Iovance Biotherapeutics to Begin Clinical Trials of Gene-Edited TIL Therapy in Melanoma, NSCLC

 Source: Precision Oncology News, March 2022

NEW YORK – Iovance Biotherapeutics on Tuesday said it has gotten permission from the US Food and Drug Administration to begin clinical trials of its gene-edited, autologous tumor-infiltrating lymphocyte (TIL) treatment in advanced melanoma and non-small cell lung cancer patients.

The FDA cleared Iovance’s investigational new drug application for IOV-4001, which the company will now study in patients with unresectable or metastatic melanoma and stage III or IV NSCLC. The therapy involves harvesting patients’ TILs and using a gene-editing technology, dubbed TALEN, to modify the TILs such that the gene coding for the PD-1 protein becomes inactivated. This allows T cells to recognize and attack cancer cells.